UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/588,171	01/04/2007	Peter Joseph Ayre	CU-4989 EJC	5161
26530 LADAS & PAF	7590 01/13/200 RRY LLP	EXAMINER		
224 SOUTH MICHIGAN AVENUE			LAVERT, NICOLE F	
	SUITE 1600 CHICAGO, IL 60604		ART UNIT	PAPER NUMBER
			3762	
			MAIL DATE	DELIVERY MODE
			01/13/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/588,171	AYRE ET AL.				
Office Action Summary	Examiner	Art Unit				
	NICOLE F. LAVERT	3762				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	<b>J.</b> nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>08 Oc</u>	ctober 2008.					
	action is non-final.					
<i>;</i> —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-3,5 and 7-12</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrav	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-3,5 and 7-12</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)⊠ The drawing(s) filed on <u>31 March 2008</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
	priority under 35 LLS C & 110(a)	(d) or (f)				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
,— ,— ,—						
	1. Certified copies of the priority documents have been received.					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)		(DTO 440)				
1) X Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ∐ Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08)  5) Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) Other:						

Art Unit: 3762

### **DETAILED ACTION**

# Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 1-3, 5, 8 & 11-12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Due to the subject matter of the claim 1 limitation, "...first and second connectors...configured for mutual connection wholly external of the patient body," not being described in the specification the above claims are failing to comply with the written description requirement.

## Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 1. Claims 1-3, 5 & 7-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Jarvik (US 5,904,646).

Art Unit: 3762

Jarvik discloses, a percutaneous lead assembly configured to supply electrical signals to a medical device Implanted within a body of a patient, said lead assembly comprising (e.g., col 2, ln 10-12 & 22-26): a flexible elongate member having a first portion adapted to remain external to the body of the patient (e.g., Fig 1, 57); and a second portion adapted to extend through a hole in a skin layer of the body of the patient (e.g., Fig 1, 33): a first connector on an end of the first portion (e.g., Fig 1, 60); and a second connector on an end of the second portion (e.g., Fig 1, 30), wherein the first and second connectors are releasably mutually connectable and configured for mutual connection wholly externally of the patient body [e.g., (col 2, ln 22-26) & (col 3, ln 24-49 & 56-64)].

# Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 3762

4. **Claims 9-12** are rejected under 35 U.S.C. 103(a) as being unpatentable over Jarvik (US 5,904,646) in view of Hampton et al. (US 2003/0028148).

Jarvik discloses the claimed invention having a percutaneous lead assembly except for said assembly comprising a first and second portion, wherein the second portion has a second diameter which is smaller than the first diameter. Hampton et al. teaches that it is known to use an apparatus for fastening and stabilizing a intravenous medical tubing including a tubing holder used to hold and secure said medical tubing, in which said tubing holder has a larger diameter than that of the medical tubing {e.g., [0020] & (Fig 1, 100 & 102)}. Note that the Examiner is interpreting the medical tubing and intravenous medical tubing as being the first and second portions instantly claimed. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the lead assembly as taught by Jarvik with the tubing holder and medical tubing, having a smaller diameter than that of the tubing holder, as taught by Hampton et al., since such a modification would provide the percutaneous lead assembly wherein the second portion has a second diameter which is smaller than the first diameter as is instantly claimed for providing the predictable results pertaining to effectively stabilizing and fastening medical tubing by way of a larger diameter structure coupled to medical tubing, which is defined by a smaller diameter {Hampton, [0002] & (Fig 1, 100 & 102)}.

# Response to Arguments

5. Applicant's arguments with respect to claims 1-3, 5 & 7-12 have been considered but are moot in view of the new ground(s) of rejection as necessitated by amendments.

Art Unit: 3762

#### Conclusion

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLE F. LAVERT whose telephone number is (571)270-5040. The examiner can normally be reached on M-F 7:30-5:00p.m. (alt. fridays).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on 571-272-4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3762

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/George R Evanisko/ Primary Examiner, Art Unit 3762

/Nicole F. LaVert/ Examiner, Art Unit 3762